---
title: Obinutuzumab
description: 'Obinutuzumab is prescribed for the treatment of:'
is_banned: false
lastModified: '2025-09-22T17:21:53.751Z'
faqs:
  - q: >-
      What is the recommended dosage for Obinutuzumab?**


      **A:** The dosage depends on the indication (CLL or FL) and the treatment
      cycle. Please refer to the detailed dosage section above for specific
      regimens.
    a: >-
      A:** The dosage depends on the indication (CLL or FL) and the treatment
      cycle. Please refer to the detailed dosage section above for specific
      regimens.
  - q: >-
      What are the most common side effects of Obinutuzumab?**


      **A:** The most common side effects include infusion-related reactions,
      neutropenia, thrombocytopenia, fatigue, cough, and infections.
    a: >-
      A:** The most common side effects include infusion-related reactions,
      neutropenia, thrombocytopenia, fatigue, cough, and infections.
  - q: >-
      What are the serious side effects of Obinutuzumab?**


      **A:** Serious side effects can include hepatitis B reactivation,
      progressive multifocal leukoencephalopathy (PML), and tumor lysis syndrome
      (TLS).
    a: >-
      A:** Serious side effects can include hepatitis B reactivation,
      progressive multifocal leukoencephalopathy (PML), and tumor lysis syndrome
      (TLS).
  - q: >-
      How are infusion reactions managed?**


      **A:** Premedication with antihistamines, corticosteroids, and
      antipyretics is recommended. Interrupt or slow the infusion rate for grade
      1 or 2 reactions.  Stop the infusion for grade 3 or 4 reactions.
    a: >-
      A:** Premedication with antihistamines, corticosteroids, and antipyretics
      is recommended. Interrupt or slow the infusion rate for grade 1 or 2
      reactions.  Stop the infusion for grade 3 or 4 reactions.
  - q: >-
      Can Obinutuzumab be used in patients with renal impairment?**


      **A:**  No dose adjustment is recommended, but use with caution in
      patients with creatinine clearance <50 ml/min. Closely monitor these
      patients.
    a: >-
      A:**  No dose adjustment is recommended, but use with caution in patients
      with creatinine clearance <50 ml/min. Closely monitor these patients.
  - q: >-
      What monitoring parameters are essential during Obinutuzumab treatment?**


      **A:**  Regular monitoring of complete blood counts (CBC) with
      differential, liver function tests, and HBV serologies (before and during
      treatment) is necessary.
    a: >-
      A:**  Regular monitoring of complete blood counts (CBC) with differential,
      liver function tests, and HBV serologies (before and during treatment) is
      necessary.
  - q: >-
      Is Obinutuzumab safe to use during pregnancy or breastfeeding?**


      **A:**  No. Obinutuzumab can cause fetal harm and is contraindicated
      during pregnancy and breastfeeding.  Effective contraception should be
      used during treatment and for 6 months following the last dose. 
      Breastfeeding should be discontinued during treatment and for 6 months
      after the last dose.
    a: >-
      A:**  No. Obinutuzumab can cause fetal harm and is contraindicated during
      pregnancy and breastfeeding.  Effective contraception should be used
      during treatment and for 6 months following the last dose.  Breastfeeding
      should be discontinued during treatment and for 6 months after the last
      dose.
  - q: >-
      What is the mechanism of action of Obinutuzumab?**


      **A:** Obinutuzumab binds to the CD20 antigen on B cells, leading to their
      depletion through antibody-dependent cell-mediated cytotoxicity (ADCC),
      complement-dependent cytotoxicity (CDC), and direct cell death.
    a: >-
      A:** Obinutuzumab binds to the CD20 antigen on B cells, leading to their
      depletion through antibody-dependent cell-mediated cytotoxicity (ADCC),
      complement-dependent cytotoxicity (CDC), and direct cell death.
  - q: >-
      How is Obinutuzumab administered?**


      **A:** Obinutuzumab is administered intravenously as an infusion. It
      should never be given as an IV push or bolus.
    a: >-
      A:** Obinutuzumab is administered intravenously as an infusion. It should
      never be given as an IV push or bolus.
  - q: >-
      What are the contraindications to using Obinutuzumab?**


      **A:**  Known hypersensitivity to obinutuzumab or any of its components,
      and a history of serum sickness with prior obinutuzumab use.
    a: >-
      A:**  Known hypersensitivity to obinutuzumab or any of its components, and
      a history of serum sickness with prior obinutuzumab use.
---
## **Usage**

Obinutuzumab is prescribed for the treatment of:

* **Chronic Lymphocytic Leukemia (CLL):**  In combination with chlorambucil for previously untreated CLL.
* **Follicular Lymphoma (FL):** 
    * In combination with bendamustine followed by obinutuzumab monotherapy for patients with FL who have relapsed after, or are refractory to, a rituximab-containing regimen.
    * In combination with chemotherapy followed by obinutuzumab monotherapy for adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma.

**Pharmacological Classification:**  Obinutuzumab is a monoclonal antibody, specifically a CD20-directed cytolytic antibody.

**Mechanism of Action:** Obinutuzumab binds to the CD20 antigen found on the surface of B-cells (both normal and malignant). This binding triggers antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death, leading to the depletion of B-cells.


## **Alternate Names**

* **International Nonproprietary Name (INN):**  obinutuzumab
* **Brand Name:** Gazyva, Gazyvaro


## **How It Works**

**Pharmacodynamics:** Obinutuzumab primarily targets CD20-expressing B-cells, causing their depletion via ADCC, CDC, and direct cell death. This leads to a decrease in the malignant B-cell population in CLL and FL.

**Pharmacokinetics:**

* **Absorption:** Administered intravenously; therefore, complete bioavailability is assumed.
* **Distribution:** Exhibits target-mediated drug disposition, with initial rapid depletion due to binding to CD20-positive cells, followed by a linear clearance phase.
* **Metabolism:**  As a monoclonal antibody, metabolism is likely through catabolism to small peptides and amino acids.
* **Elimination:** Primarily through protein catabolism; minimal renal or hepatic elimination is expected.

**Mode of Action:** Obinutuzumab binds to the CD20 antigen, a cell surface protein expressed on B-cells. This binding triggers multiple mechanisms of cell death, including ADCC (mediated by natural killer cells and macrophages), CDC (mediated by the complement system), and direct cell death.

**Receptor Binding:** Binds specifically to the CD20 antigen.

**Elimination Pathways:**  Primarily through protein catabolism.



## **Dosage**


### **Standard Dosage**

#### **Adults:**

* **CLL (with chlorambucil):** 
    * Cycle 1: 100 mg IV on Day 1, 900 mg IV on Day 2, 1000 mg IV on Days 8 and 15.
    * Cycles 2-6: 1000 mg IV on Day 1 of each cycle.

* **FL (with bendamustine or chemotherapy):**
    * Cycle 1: 1000 mg IV on Days 1, 8, and 15.
    * Cycles 2-6 (or 2-8): 1000 mg IV on Day 1 of each cycle.
    * Maintenance (if complete or partial response): 1000 mg IV every 2 months for up to 2 years.

All infusions should be administered over a specified period, starting at a slow rate and increasing gradually as tolerated.

#### **Children:**  The safety and efficacy of obinutuzumab in children and adolescents below 18 years have not been established.


#### **Special Cases:**

* **Elderly Patients:** No specific dose adjustment is recommended, but elderly patients should be monitored closely for adverse reactions.
* **Patients with Renal Impairment:** No dose adjustment is recommended based on limited available data. However, use with caution in patients with creatinine clearance < 50 mL/min.
* **Patients with Hepatic Dysfunction:** The safety and efficacy have not been established in patients with hepatic impairment. No specific dose recommendations can be made.
* **Patients with Comorbid Conditions:** Patients with cardiovascular or respiratory disease should be monitored carefully, particularly during and after infusions. Premedication for infusion reactions is essential.


### **Clinical Use Cases**  

Obinutuzumab is not indicated for intubation, surgical procedures, mechanical ventilation, ICU use, or emergency situations like cardiac arrest. Its use is specifically for CLL and FL, as outlined above.

### **Dosage Adjustments**  

Dose adjustments may be necessary based on patient tolerance to infusion reactions or hematological toxicity. Monitor blood counts regularly.


## **Side Effects**

### **Common Side Effects**
Infusion-related reactions, neutropenia, thrombocytopenia, fatigue, cough, upper respiratory tract infection, nausea, diarrhea, pyrexia, and musculoskeletal pain.

### **Rare but Serious Side Effects**
Hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), tumor lysis syndrome (TLS), severe infusion reactions, and opportunistic infections.

### **Long-Term Effects**
Prolonged immunosuppression, increased risk of secondary malignancies.


### **Adverse Drug Reactions (ADR)**
Severe infusion reactions (including anaphylaxis), hepatitis B reactivation, PML, TLS, and severe cytopenias.


## **Contraindications**
Known hypersensitivity to obinutuzumab or any of its components, prior serum sickness with obinutuzumab.


## **Drug Interactions**
Numerous drug interactions exist. Refer to a comprehensive drug interaction database for a complete list. Concomitant use of other myelosuppressive agents can exacerbate cytopenias.  Live virus vaccines should be avoided during treatment and until B-cell recovery.


## **Pregnancy and Breastfeeding**
Obinutuzumab can cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for 6 months after the last dose. Breastfeeding is contraindicated during treatment and for 6 months after the last dose.

## **Drug Profile Summary**
* **Mechanism of Action:** Binds to CD20, leading to B-cell depletion via ADCC, CDC, and direct cell death.
* **Side Effects:** Infusion reactions, neutropenia, thrombocytopenia, fatigue, infection risk. Serious side effects: HBV reactivation, PML, TLS.
* **Contraindications:** Hypersensitivity to obinutuzumab, prior serum sickness.
* **Drug Interactions:**  Numerous drug interactions exist; consult a database. Avoid live vaccines.
* **Pregnancy & Breastfeeding:** Contraindicated.
* **Dosage:** Varies depending on indication and cycle. See detailed dosing information above.
* **Monitoring Parameters:**  Complete blood count (CBC) with differential, liver function tests, HBV serologies (before and during treatment).



## **Popular Combinations**
* Obinutuzumab + chlorambucil (for CLL)
* Obinutuzumab + bendamustine (for FL)
* Obinutuzumab + chemotherapy regimens (e.g., CHOP, CVP) for FL


## **Precautions**
Screen all patients for HBV infection before starting treatment. Monitor for HBV reactivation during and after treatment. Patients with pre-existing cardiovascular or pulmonary conditions require close monitoring during infusions. Prophylactic measures for infusion reactions and TLS should be taken. 

## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Obinutuzumab?**

**A:** The dosage depends on the indication (CLL or FL) and the treatment cycle. Please refer to the detailed dosage section above for specific regimens.

### **Q2: What are the most common side effects of Obinutuzumab?**

**A:** The most common side effects include infusion-related reactions, neutropenia, thrombocytopenia, fatigue, cough, and infections.

### **Q3: What are the serious side effects of Obinutuzumab?**

**A:** Serious side effects can include hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), and tumor lysis syndrome (TLS).

### **Q4:  How are infusion reactions managed?**

**A:** Premedication with antihistamines, corticosteroids, and antipyretics is recommended. Interrupt or slow the infusion rate for grade 1 or 2 reactions.  Stop the infusion for grade 3 or 4 reactions.

### **Q5: Can Obinutuzumab be used in patients with renal impairment?**

**A:**  No dose adjustment is recommended, but use with caution in patients with creatinine clearance <50 ml/min. Closely monitor these patients.

### **Q6: What monitoring parameters are essential during Obinutuzumab treatment?**

**A:**  Regular monitoring of complete blood counts (CBC) with differential, liver function tests, and HBV serologies (before and during treatment) is necessary.

### **Q7: Is Obinutuzumab safe to use during pregnancy or breastfeeding?**

**A:**  No. Obinutuzumab can cause fetal harm and is contraindicated during pregnancy and breastfeeding.  Effective contraception should be used during treatment and for 6 months following the last dose.  Breastfeeding should be discontinued during treatment and for 6 months after the last dose.


### **Q8: What is the mechanism of action of Obinutuzumab?**

**A:** Obinutuzumab binds to the CD20 antigen on B cells, leading to their depletion through antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death.

### **Q9: How is Obinutuzumab administered?**

**A:** Obinutuzumab is administered intravenously as an infusion. It should never be given as an IV push or bolus.

### **Q10: What are the contraindications to using Obinutuzumab?**

**A:**  Known hypersensitivity to obinutuzumab or any of its components, and a history of serum sickness with prior obinutuzumab use.
